Meeting Banner
Abstract #0813

Inhibition of Prostate Cancer Growth by Deferiprone

Rui V. Simoes1, Natalia Kruchevsky1, Inna Serganova2, Ellen Ackestaff1, George Sukenick3, Ronald G. Blasberg2, 4, Jason A. Koutcher1, 5

1Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, United States; 2Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, United States; 3NMR Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, United States; 4Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States; 5Weill Cornell Medical College, Cornell University, New York, NY, United States

Activation of mitochondrial aconitase (m-acon) is an early biochemical change during prostate cancer (PCa) development, leading to a shift from citrate-producing to a citrate-oxidizing malignant phenotype. Deferiprone (DFP), an iron chelator used in the clinic has been shown to impair aconitase activity and inhibit cell growth. We have studied the effects of DFP on TRAMP C2 cells. DFP induced a marked decrease in TRAMP C2 cell growth (IC50=49 M), affecting many metabolic parameters detected by 31P and 13C-MRS, and decreasing cellular oxygen consumption. Our results show the potential of DFP to inhibit PCa growth at clinically relevant doses.

Abstract PDF Presentation Video

Keywords

acknowledgments activation activity affected agrees alanine analyses analyzer assay assessed besides beta biochemical bioscience blood blot cancer carried cell cells cellular chain choline citrate clinic clinically college compatible complex concentrations conditions consequent consistent consumption core counting coupled cultured cycle days decrease decreased derived described detected determined development discarded dose doses doubling drug earlier early energy essential essentially experiment explain exposed exposure expression facility flux fold foster function generated glucose glutamate glycerol grant grants grown growth guava impair incubation induced inhibit inhibition inhibitors investigate investigated investigating iron lactate leading live malignant marked measured measuring medical memorial metabolism metabolites migration monitoring mouse neurology ongoing oxidate oxidizing oxygen partially peak perfusion periods phenotype phosphate physics plastic plus potential previously producing production prostate quantifications quickly radiology regular relevant removing repeated respectively respiratory response scratch seahorse significantly since spectral spectrometer studied support supported synthesis system target targets technologies terms therapy tramp vitro western